Lyon Consensus 2.0 Shifts GERD Diagnosis Toward Objective Evidence in Asia
The updated Lyon Consensus 2.0 changes the diagnostic conversation in gastroesophageal reflux disease by moving away from symptom-led labeling and toward measurable physiology. In Asia, where access to esophageal testing can remain uneven and regional reference values may differ from Western cohorts, the framework forces a practical question: how much objective evidence is enough to call reflux disease and how should that evidence be gathered when ideal testing is not always available?
This review places the new consensus into an Asian clinical setting and makes a strong case for diagnostic flexibility without abandoning rigor. Prolonged wireless pH monitoring now sits more prominently in the pathway, while pH-impedance testing remains central when symptoms are atypical, refractory, or dominated by regurgitation. The revised framework also accepts Los Angeles grade B esophagitis as conclusive evidence of GERD, a change that matters because it increases the number of patients who can receive a firm diagnosis without waiting for more complex studies.
A single endoscopic finding can now change the diagnostic path.
That matters in Asian health systems, where endoscopy is often more accessible than ambulatory reflux monitoring. In settings where primary care cannot routinely provide physiological testing, an endoscopy-based approach may help close the gap between symptom burden and diagnostic certainty. The tradeoff is obvious: endoscopy alone will not characterize every reflux phenotype, but it can identify patients who already have objective mucosal injury and therefore need less ambiguity in their next step of care.
Regional Thresholds, Reflux Phenotypes, and the Problem With Imported Norms
Lyon Consensus 2.0 retains the principle that GERD should be confirmed objectively, yet the review argues that Western-derived cutoffs do not map cleanly onto Asian populations. Lower acid exposure thresholds may be needed, and that possibility is not a statistical footnote. It speaks to differences in physiology, disease prevalence, referral patterns, and the way local populations present to care. A threshold that works in one region can miss clinically relevant disease in another, especially when patients sit in a gray zone between functional symptoms and reflux injury.
The revised approach also recognizes the value of mean nocturnal baseline impedance in pH-impedance studies. This metric reflects mucosal integrity and provides another window into esophageal barrier function, especially when acid exposure time alone does not tell the full story. In practical terms, the addition of more refined impedance measures allows clinicians to separate persistent reflux physiology from symptoms driven by hypersensitivity or hypervigilance.
High-resolution manometry still has a major role. It helps define esophageal motor patterns, clarifies anatomy and barrier function, and supports interpretation of refractory symptoms. In regurgitation-predominant disease, manometry and impedance together can identify patients whose complaints reflect impaired anti-reflux barrier mechanics rather than acid burden alone. For a disorder often diagnosed after long delays and repeated empiric therapy, that distinction can redirect treatment before more medications are layered on top of each other.
Actionable GERD and the New Role of Anti-Reflux Barrier Metrics
The idea of actionable GERD is one of the most useful changes in the updated consensus. It shifts the goal from simply proving that reflux exists to identifying whether the reflux physiology is likely to respond to a specific intervention. In other words, diagnosis becomes therapeutic triage. A patient may have symptoms compatible with reflux, but treatment choices become more precise when objective data show whether the issue is acid burden, mechanical barrier failure, or something more consistent with functional symptoms.
The review reporting the Milan score as a new manometry-based index that evaluates anti-reflux barrier integrity. Its attraction lies in its mechanistic logic: if the barrier is failing, especially at the gastroesophageal junction, then endoscopic anti-reflux therapies may be more rational candidates than repeated acid suppression alone. The score has particular appeal in systems where procedure selection must be efficient and where patients often arrive after empiric treatment has already failed.
The clinical utility here is not abstract. Patients with refractory symptoms frequently cycle through proton pump inhibitors, reassurance, and repeated reassessment without a physiologic diagnosis. A barrier-focused tool offers a more direct route to phenotype the disease. When barrier integrity is poor, the signal points toward structural or mechanical treatment strategies; when it is preserved, clinicians should look harder for non-reflux explanations or mixed syndromes.
Laryngeal Symptoms, Psychophysiology, and the Limits of Purely Mechanical Thinking
The review also discusses the COuGH RefluX score, which estimates GERD probability in patients with laryngeal complaints using symptoms and risk factors. This is useful because extraesophageal symptoms often sit at the intersection of gastroenterology, otolaryngology, and psychology, and they are among the hardest presentations to sort out with a single test. A structured probability tool can help decide who needs objective reflux testing rather than open-ended empiricism.
Psychophysiological assessment adds another layer of precision. Esophageal hypervigilance and symptom-related anxiety can amplify symptom perception, prolong diagnostic uncertainty, and reduce the apparent benefit of otherwise appropriate therapy. These are not peripheral concerns. In patients whose symptom burden exceeds the objective reflux signal, mental and sensory amplification can distort both the presentation and the response to treatment. Incorporating these dimensions can prevent overdiagnosis of reflux disease and reduce unnecessary escalation of acid suppression or procedural intervention.
This is where the consensus becomes more clinically mature. It accepts that reflux symptoms do not always map neatly onto acid exposure, and that patient experience is shaped by both physiology and perception. A rigid diagnostic model would miss those interactions. An expanded model can identify the subset of patients whose symptoms are driven by reflux physiology, those with mixed mechanisms, and those whose complaints need a different therapeutic frame altogether.
What Asian Implementation Will Depend On at the Bedside
The review’s central message is straightforward: Lyon Consensus 2.0 can improve GERD care in Asia only if the framework is adapted to regional realities. Objective testing remains the backbone of diagnosis, but access limitations make a purely idealized pathway unrealistic for many settings. Endoscopy, wireless pH monitoring, pH-impedance, and high-resolution manometry each have a role, yet they answer different questions and are not interchangeable.
Regional adaptation will also require willingness to revisit imported thresholds and to validate diagnostic scores in local populations. Western-derived tools may underperform when applied unchanged to Asian patients, and that creates risk in both directions: overcalling GERD in some patients and missing physiologically meaningful disease in others. The review makes clear that the path forward is not a simplified checklist but a regionally calibrated framework that links physiology, symptoms, and treatment selection.
For clinicians, the practical implication is narrower and more demanding. Diagnosis should rest on objective evidence whenever possible, but the evidence must be interpreted through the lens of local availability, local thresholds, and the patient’s symptom phenotype. Without that adaptation, the promise of actionable GERD will remain unevenly applied and patients with reflux-predominant disease will continue to move through care without a precise physiologic label.